Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept with Delayed Sirolimus in Renal Transplant
NCT02686619Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2004
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in kidney transplantation (2 arms), sponsored by Roche. Primary endpoints: Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at 60 months, Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months and 4 more. Started Nov 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT02686619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686619.